Blackstone Inc
DNTH icon

Blackstone Inc’s Dianthus Therapeutics DNTH Stock Holding History

Blackstone Inc’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.94M Buy
+35,045
New +$2.03M 0.01% 165
2018
Q3 		– Sell
-1,094
Closed -$236K – 59
2018
Q2 		$236K Buy
+1,094
New +$247K ﹤0.01% 80

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Blackstone Inc's DNTH Position: Q1 2026 in Review

Blackstone Inc opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 35,045 shares worth $2.94M. The stake represents 0.01% of the portfolio and ranks #165 among its holdings. This is a return to the name: Blackstone Inc previously reported a position in DNTH as recently as Q2 2018.

Blackstone Inc first reported a position in DNTH in Q2 2018 and has held it in 2 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Blackstone Inc held 35,045 shares of Dianthus Therapeutics worth $2.94M as of Q1 2026.
  • Dianthus Therapeutics was a new Blackstone Inc position in Q1 2026.
  • Dianthus Therapeutics made up 0.01% of Blackstone Inc's portfolio in Q1 2026, its #165 holding.
  • Blackstone Inc first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.